Acer Therapeutics Inc. (ACER): Price and Financial Metrics

Acer Therapeutics Inc. (ACER)

Today's Latest Price: $5.10 USD

0.01 (0.20%)

Updated Aug 11 2:03pm

Add ACER to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ACER Daily Price Range
ACER 52-Week Price Range

ACER Stock Price Chart Technical Analysis Charts

ACER Price/Volume Stats

Current price $5.10 52-week high $7.25
Prev. close $5.09 52-week low $1.08
Day low $4.77 Volume 679,369
Day high $5.43 Avg. volume 221,588
50-day MA $3.55 Dividend yield N/A
200-day MA $3.38 Market Cap 52.27M

Acer Therapeutics Inc. (ACER) Company Bio

Acer Therapeutics Inc., formerly Opexa Therapeutics, develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease. It also offers advancing ACER-001 for the treatment of urea cycle disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.

ACER Latest News Stream

Event/Time News Detail
Loading, please wait...

ACER Latest Social Stream

Loading social stream, please wait...

View Full ACER Social Stream

Latest ACER News From Around the Web

Below are the latest news stories about Acer Therapeutics Inc that investors may wish to consider to help them evaluate ACER as an investment opportunity.

Insider Buys Acer Therapeutics's Shares

Shares of Acer Therapeutics Inc (NASDAQ:ACER) moved higher by 7.5% from the previous closing price. A Form 4 filing filed with the SEC on Tuesday, July 28 showed that President & CEO Schelling Chris bought 142,857 shares at an average price of $3.50. The transaction moved the executive's stake in Acer Therapeutics Inc. to 1,892,857 shares.The Importance of Insider Transactions While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an insider buying or selling stock in their company can be a good added factor that leads to more conviction in a decision.When an insider buys stock after an important sell off, that can indicate the insider's faith in the success of the organization. Henceforth, if the stock is bought at n...

Yahoo | July 28, 2020

Lifshitz Law Firm, P.C. Announces Investigation of Acer Therapeutics, Inc. (ACER), Advanced Disposal Services, Inc. (ADSW), Apyx Medical Corporation (APYX), Honeywell International Inc. (HON), Immunomedics, Inc. (IMMU), National General Holdings Corp. (NGHC) and Zuora, Inc. (ZUO)

Acer Therapeutics, Inc. (ACER)

Yahoo | July 9, 2020

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Acer Therapeutics Inc. (ACER)

Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Acer Therapeutics Inc. (NYSE: ACER) for breaches of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of the Securities Exchange Act of 1934. Acer is a pharmaceutical company that focuses on the development and commercialization of therapies for rare diseases. One of its medications is EDVISO (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome ("vEDS").

Yahoo | July 9, 2020

Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study

Model suggests ACER-001, Acer’s taste-masked, immediate release formulation of sodium phenylbutyrate, may offer improved disease management in patients with Urea Cycle Disorders.

Yahoo | July 8, 2020

The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Acer Therapeutics Inc. Investors (ACER)

LOS ANGELES--(BUSINESS WIRE)---- $ACER #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Acer Therapeutics Inc. (“Acer” or the “Company”) (NASDAQ: ACER) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click here to participate. On June 25, 2019, the Company disclosed receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration rejecting its new drug application for EDSIVO,

Business Wire | June 24, 2020

Read More 'ACER' Stories Here

ACER Price Returns

1-mo 45.71%
3-mo 40.11%
6-mo 9.21%
1-year 120.78%
3-year -39.17%
5-year -84.21%
YTD 27.18%
2019 -80.07%
2018 45.27%
2017 45.45%
2016 -66.79%
2015 -51.91%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.806 seconds.